Literature DB >> 9776110

Study of pro-inflammatory (TNF-alpha, IL-1alpha, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: correlations with clinical and laboratory parameters.

N Kutukculer1, S Caglayan, F Aydogdu.   

Abstract

Acute phase proteins, synovial fluid (SF) cellular infiltrates, pro-inflammatory (TNF-alpha, IL-1alpha, IL-6) and Th1 (IL-2) and Th2 (IL-4) derived cytokine levels both in plasma and SF were examined in pauciarticular and polyarticular juvenile chronic arthritis (JCA) patients during the active (n = 22) and inactive (n = 14) period in order to determine pathogenic mechanisms and correlations between cytokines and laboratory parameters showing disease activity. The erythrocyte sedimentation rate (ESR), serum C-reactive protein (CRP) and IgG concentrations were found to be significantly elevated in the active period of JCA. In pauciarticular JCA patients, when compared with their peripheral blood lymphocyte subpopulations, SF CD3+ cells (73.1%) and HLA-DR+ active T cells (22.5%) were found to be significantly increased. In the active period of JCA, plasma TNF-alpha and IL-6 concentrations were significantly elevated. Plasma IL-2 and IL-4 levels were not elevated and were found to be similar to those in the inactive phase and in healthy controls. SF IL-6, TNF-alpha and IL-1alpha levels were extremely high in all the patients. SF IL-4 and IL-2 levels were all undetectable. There was a significant correlation between ESR values and plasma IL-6 levels and between serum CRP levels and plasma IL-6 and TNF-alpha concentrations. In conclusion, increased local production of pro-inflammatory cytokines appears to account for the articular manifestations of JCA. The impaired production of anti-inflammatory Th2-derived cytokines (IL-4) seems to cause increased production of inflammatory cytokines acting on the balance between them. The deficit in IL-2 production was not suggested to be primarily involved in the pathogenesis. In addition, not only CRP and ESR values, but also plasma IL-6 and TNF-alpha concentrations may be used as markers of disease activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9776110     DOI: 10.1007/bf01451007

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  18 in total

1.  Inhibition of the production of proinflammatory cytokines and immunoglobulins by interleukin-4 in an ex vivo model of rheumatoid synovitis.

Authors:  P Miossec; J Briolay; J Dechanet; J Wijdenes; H Martinez-Valdez; J Banchereau
Journal:  Arthritis Rheum       Date:  1992-08

2.  Arthritogenic actions of recombinant IL-1 and tumour necrosis factor alpha in the rabbit: evidence for synergistic interactions between cytokines in vivo.

Authors:  B Henderson; E R Pettipher
Journal:  Clin Exp Immunol       Date:  1989-02       Impact factor: 4.330

3.  Correlation of synovial fluid interleukin 6 (IL-6) activities with IgG concentrations in patients with inflammatory joint disease and osteoarthritis.

Authors:  E Hermann; B Fleischer; W J Mayet; T Poralla; K H Meyer zum Büschenfelde
Journal:  Clin Exp Rheumatol       Date:  1989 Jul-Aug       Impact factor: 4.473

4.  Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritis.

Authors:  B A Eberhard; R M Laxer; U Andersson; E D Silverman
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

5.  Circulating levels of interleukin 1 beta and of interleukin 1 receptor antagonist in systemic juvenile chronic arthritis.

Authors:  F De Benedetti; P Pignatti; M Massa; P Sartirana; A Ravelli; A Martini
Journal:  Clin Exp Rheumatol       Date:  1995 Nov-Dec       Impact factor: 4.473

6.  Serum interleukin-6 levels and joint involvement in polyarticular and pauciarticular juvenile chronic arthritis.

Authors:  F De Benedetti; P Robbioni; M Massa; S Viola; S Albani; A Martini
Journal:  Clin Exp Rheumatol       Date:  1992 Sep-Oct       Impact factor: 4.473

7.  Study of IL-2, IL-6, TNF alpha, IFN gamma and beta in the serum and synovial fluid of patients with juvenile chronic arthritis.

Authors:  L Lepore; M Pennesi; S Saletta; S Perticarari; G Presani; M Prodan
Journal:  Clin Exp Rheumatol       Date:  1994 Sep-Oct       Impact factor: 4.473

8.  Augmented numbers of HLA-DR-positive T lymphocytes in the synovial fluid and synovial tissue of patients with rheumatoid arthritis and juvenile rheumatoid arthritis: in vivo-activated T lymphocytes are potent stimulators in the mixed lymphocyte reaction.

Authors:  O Førre; J H Dobloug; J B Natvig
Journal:  Scand J Immunol       Date:  1982-02       Impact factor: 3.487

9.  Interleukin-6 and soluble interleukin-2 receptor in juvenile chronic arthritis: correlations with clinical and laboratory parameters.

Authors:  A Spadaro; V Riccieri; A Sili Scavalli; F Sensi; D Fiore; E Taccari; A Zoppini
Journal:  Rev Rhum Engl Ed       Date:  1996-03

10.  Inflammatory cytokine responses in juvenile chronic arthritis.

Authors:  M Rooney; J David; J Symons; F Di Giovine; H Varsani; P Woo
Journal:  Br J Rheumatol       Date:  1995-05
View more
  31 in total

Review 1.  Type 1 and type 2 immune responses in children: their relevance in juvenile arthritis.

Authors:  L R Wedderburn; P Woo
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Proinflammatory cytokines, IL-1β and TNF-α, induce expression of interleukin-34 mRNA via JNK- and p44/42 MAPK-NF-κB pathway but not p38 pathway in osteoblasts.

Authors:  Hiroyuki Eda; Hideaki Shimada; David R Beidler; Joseph B Monahan
Journal:  Rheumatol Int       Date:  2010-12-23       Impact factor: 2.631

3.  Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study.

Authors:  Wilco de Jager; Esther P A H Hoppenreijs; Nico M Wulffraat; Lucy R Wedderburn; Wietse Kuis; Berent J Prakken
Journal:  Ann Rheum Dis       Date:  2006-12-14       Impact factor: 19.103

4.  Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study.

Authors:  Norman Ilowite; Oscar Porras; Andreas Reiff; Sue Rudge; Marilynn Punaro; Alan Martin; Roger Allen; Terry Harville; Yu-Nien Sun; Terry Bevirt; Gary Aras; Brent Appleton
Journal:  Clin Rheumatol       Date:  2008-09-03       Impact factor: 2.980

Review 5.  The use of anakinra in juvenile arthritis.

Authors:  Andreas Reiff
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

6.  Serum amyloid A induces mitogenic signals in regulatory T cells via monocyte activation.

Authors:  Khoa D Nguyen; Claudia Macaubas; Phi Truong; Nan Wang; Tieying Hou; Taejin Yoon; Elizabeth D Mellins
Journal:  Mol Immunol       Date:  2014-03-13       Impact factor: 4.407

Review 7.  The development and assessment of biological treatments for children.

Authors:  Eve M D Smith; Helen E Foster; Michael W Beresford
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

8.  New approaches to sepsis: molecular diagnostics and biomarkers.

Authors:  Konrad Reinhart; Michael Bauer; Niels C Riedemann; Christiane S Hartog
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

Review 9.  Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis.

Authors:  Kristen Hayward; Carol A Wallace
Journal:  Arthritis Res Ther       Date:  2009-02-23       Impact factor: 5.156

10.  Challenges in the management of juvenile idiopathic arthritis with etanercept.

Authors:  Clare E Pain; Liza J McCann
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.